Clinical Nutrition System
Clinical Nutrition System
A protocol-driven, clinical nutrition system to preserve lean muscle mass, support gut health, and sustain metabolic outcomes for patients on GLP-1 therapy, during transition, and beyond.
The SunRise Nutrition System is built around a differentiated "triple-action" sunflower ingredient platform — a single botanical source delivering three clinically relevant mechanisms: high-quality protein, prebiotic soluble fiber, and chlorogenic acid.
High leucine-content sunflower protein supports muscle protein synthesis during the hypocaloric state induced by GLP-1 therapy, addressing the critical challenge of lean mass loss — up to 39% of total weight lost — in GLP-1 users.
Nextida™ GC collagen peptides are clinically studied to support a healthy postprandial glucose response when taken before meals (Grasset et al., 2024). This positions the ingredient as a mealtime adjunct for patients managing glycemic stability during and after GLP-1 therapy.
A three-source soluble fiber stack — Resistant dextrin, PHGG, and acacia gum — supports SCFA production across fast- and slow-fermenting profiles, plus ~5g intrinsic insoluble fiber from sunflower protein. Engineered for GI tolerability in the hypersensitive GLP-1 population.
Naturally occurring chlorogenic acid from sunflower supports postprandial glucose regulation through inhibition of hepatic glucose-6-phosphatase and promotion of insulin receptor sensitivity — mechanistically relevant to the metabolic health population.
Sunflower lecithin and acacia gum provide a phosphatidylcholine-rich emulsification system supporting fat-soluble micronutrient absorption — avoiding soy lecithin for allergy-sensitive patients
GLP-1 users face documented micronutrient depletion due to reduced food volume. SunRise Metabolism Plus delivers an 8-nutrient premix including D3 (800 IU), K2 MK-7, methylated B12, L-5-MTHF folate, P5P (B6), thiamine, Vitamin C, riboflavin— prioritized to the Butsch/IAPAM 2026 deficiency cohort.
| Ingredient | Primary Mechanism | Clinical Relevance | Tier Relevance |
|---|---|---|---|
| Collagen Peptides | Postprandial glucose response support (pre-meal) | Metabolic continuity post-pharmacotherapy | T2 Transition |
| Protein Blend (29g) | Leucine-mediated mTOR activation / MPS | Lean mass preservation during hypocaloric state | T1 T2 |
| Multi-Fiber Stack | SCFA production, microbiome modulation | Gut health; GLP-1–gut axis maintenance | T2 T3 |
| PHGG | Viscous fiber; gastric emptying modulation | Satiety support; GI tolerability | T1 T2 T3 |
| Chlorogenic Acid | Hepatic glucose-6-phosphatase inhibition | Postprandial glucose modulation | T3 Metabolic |
A clinically formulated nutrition shake designed to support patients at every phase of their GLP-1 journey.
Internal CGM self-testing (May 2026) of the Vanilla shake showed a favorable postprandial glucose response. Full clinical validation is planned. Data available on request.
Three representative patients. Three distinct clinical challenges. One system designed to address them all.
Marcus's endocrinologist has every reason to be pleased: A1c down from 8.1 to 6.6, blood pressure normalizing, triglycerides improving. The GLP-1 therapy is doing what it's supposed to do. But Marcus doesn't feel like a success story — he feels diminished.
The culprit is well-documented but often under-addressed. GLP-1 receptor agonists reduce total caloric intake dramatically, and without deliberate nutritional intervention, a significant portion of weight lost — estimates range from 25–39% — comes from lean mass. At 61, Marcus has limited physiological reserve to spare.
His diet diary told the story plainly: he was averaging 55–65g of protein per day, well below the 1.2–1.6g/kg target for a patient in his situation. He was also showing early signs of B-vitamin depletion — common in GLP-1 users due to dramatically reduced food volume — and reporting intermittent GI discomfort that was undermining adherence.
The SunRise Nutrition System addressed each layer of his deficiency. The shake's three-source protein system brought his daily intake to target without forcing volume he couldn't manage. The PHGG + acacia gum combination resolved his GI tolerability issues within two weeks. And the embedded micronutrient premix — specifically designed around the GLP-1 depletion pattern — addressed his fatigue at its nutritional root.
Diane's story is one you're hearing with increasing frequency. She was a model patient — consistent dosing, dietary compliance, regular follow-up. Her A1c dropped from 6.4 to 5.7. She felt better than she had in a decade. Then her insurer stopped covering the drug.
What happened next was physiologically predictable but felt like a personal failure to Diane. Endogenous GLP-1 secretion had been suppressed during pharmacotherapy. Her gut's natural satiety signaling had atrophied. Her appetite returned with a vengeance, and lean muscle she had lost during the hypocaloric phase meant her resting metabolic rate was now lower than it was before she started.
The clinical gap here is real and underserved. Diane needed a bridge: something that could support her glycemic stability while delivering the protein her muscle tissue desperately needed. SunRise Metabolism Plus — built around Nextida GC™ collagen peptides, clinically studied to support a healthy postprandial glucose response when taken before meals, paired with 29g of four-source protein including 2g of free-form L-leucine — was formulated for exactly this moment.
At 12 weeks on the system, Diane's weight regain curve had flattened. Her RD noted improved satiety scores and she reported feeling "back in control" for the first time since discontinuation.
Sandra is the most common patient in primary care and the one most likely to fall through the cracks. She doesn't qualify for GLP-1 therapy under current insurance criteria. She's motivated but overwhelmed. And she's running out of time: without meaningful intervention, 15–30% of prediabetic patients will progress to Type 2 diabetes within 5 years.
Her RD's assessment revealed a diet high in refined carbohydrates and low in both protein and fiber — a pattern that creates chronic postprandial glucose spikes and drives progressive insulin resistance. She was a candidate for structured meal replacement as part of a broader lifestyle intervention.
Metabolism Plus's T3 positioning targets exactly her metabolic profile. Chlorogenic acid from sunflower (~800mg per serving) supports postprandial glucose modulation through inhibition of hepatic glucose-6-phosphatase. The multi-source soluble fiber system (resistant dextrin, PHGG, and acacia gum) improves gut microbiome diversity — increasingly recognized as a key driver of insulin sensitivity. And the 29g four-source protein blend including 2g free-form L-leucine replaces a refined-carbohydrate meal with a high-satiety, low-glycemic alternative that supports sustainable weight management without pharmacotherapy.
Sandra's story matters beyond her individual case. The T3 population represents the largest addressable market — 96M+ Americans — and the one where nutritional intervention has its highest preventive ROI. Catching these patients before the GLP-1 threshold is reached is both clinically superior and economically rational.
The SunRise Nutrition System addresses three distinct clinical populations. Understanding the tier framework helps clinicians identify the right patients and set appropriate expectations for outcomes.
Screen for GLP-1 discontinuation plan, active use with protein gap, or metabolic risk profile.
Match to T1 (on therapy), T2 (transition), or T3 (metabolic health) based on clinical profile.
Once daily as meal replacement or protein supplement. Pre-meal use (15–30 min before largest meal) supports glycemic response; between-meal use supports satiety and protein adequacy.
Reassess protein adequacy, GI tolerance, and weight trajectory at 4-week intervals.